Arbutus to Participate at Jefferies London Healthcare Conference
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in the virtual fireside chat at the Jefferies London Healthcare Conference on November 18, 2021, at 8:00 am GMT / 3:00 am ET. Key executives, including CEO William Collier and Chief Scientific Officer Dr. Michael Sofia, will present during the event. A webcast will be available through Arbutus' website, with a replay accessible after the conference. The company focuses on developing treatments for chronic hepatitis B virus and coronaviruses, leveraging a diverse pipeline aimed at innovative solutions.
- None.
- None.
WARMINSTER, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different modes of action to provide a cure for people with chronic hepatitis B virus (HBV) infection and to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the Jefferies London Healthcare Conference.
Presenters:
William Collier, President and Chief Executive Officer; Dr. Michael Sofia, Chief Scientific Officer; Dr. Gaston Picchio, Chief Development Officer; and David Hastings, Chief Financial Officer
A webcast of the virtual fireside chat will be available beginning on Thursday, November 18, 2021 at 8:00 am GMT / 3:00 am ET, and can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com. An archived replay of the webcast will be available on the Company’s website after the conference.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different modes of action to provide a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that suppress viral replication, reduce surface antigen and reawaken the immune system. Arbutus believes this three-prong approach is key to transforming the treatment and developing a potential cure for chronic HBV infection. Arbutus’ HBV product pipeline includes RNA interference (RNAi) therapeutics, oral capsid inhibitors, oral compounds that inhibit PD-L1 and oral HBV RNA destabilizers. In addition, Arbutus has an ongoing drug discovery and development program directed to identifying orally active agents for treating coronaviruses (including COVID-19). For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
William H. Collier
President and CEO
Phone: 267-469-0914
Email: ir@arbutusbio.com
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
FAQ
What is the date of Arbutus Biopharma's virtual fireside chat at the Jefferies London Healthcare Conference?
Who will be presenting at Arbutus Biopharma's fireside chat?
What time will the Arbutus Biopharma fireside chat start?
Where can I access the webcast for Arbutus Biopharma's conference participation?
What is the focus of Arbutus Biopharma's research and development?
